Myriad: Q3 Earnings Snapshot

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $61.3 million in its third quarter.

The Salt Lake City-based company said it had a loss of 75 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 3 cents per share.

The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 8 cents per share.

The molecular diagnostic company posted revenue of $191.9 million in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $180.5 million.

Myriad expects full-year results to range from a loss of 33 cents per share to a loss of 28 cents per share, with revenue in the range of $747 million to $753 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN